SOME INTERESTING POINTS TO NOTE12 May 2021 01:12
Prof. Carl Smythe wrote in the Twitter as follows:
1. Lateral flow tests are not terribly sensitive
2. AVCT selected clinical samples with relatively high viral loads and their test can identify most of them.
3. Going forward, we need to be able to screen people to find asymptomatics.
This means that our BRH test can identify low viral loads, which would be found in asymptomatics and pre-symptomatic people.
Notes:
a) It is obviously easy to identify symptomatic people whom will have high viral loads.
b) To stop spreading of the viruses, it is important to identify asymptomatics and pre-symptomatic people and isolate them.
c) This work was not only important and procedurally adopted by BRH.
d) The issue of LFT Test Sensitivity was identified and rectified in BRH test by clearly identifying false positives and false negatives cases, and minimising and increasingly the accuracy of BRH tests.
A small hints were given in BRH RNS dated 01 & 26-Mar-2021, but was not captured by several investors and media, and traders and institutional investors. Read also the latest RNS, where Testing will be with various ranges of virons.
Hold on to this shares and avoid selling prematurely without knowing the full capabilities of BRH testing.
Hope this will give some insight for holding or buying shares in BRH/ Paraytec.
Paraytec is 100% owned by BRH, and are in the current Clinical Validation, and development headed by Prof Carl Smythe and his University of Sheffield Team.
Calm before Storm.
Keep invested and reap your harvest handsomely.
Sign In
Follow the stocks
